Hi Sam - in some instances, it depends on the form of iodine and also the other factors (hormonal) that help utilize it.
Plus - there is often the estrogen dominance factor for males and balancing that out with topical progesterone cream at 3X the standard dose has provided success as reported by restorative medicine practitioners... which would incorporate the 'massage' you initially recommended.
Found this comment on a medical blog forum:
Myomin for Prostate Problems?
Symptoms such as urination, urgency, interrupted or weak urine stream are typical of prostate issues. These can signal Benign Prostatic Hypertrophy (BPH), the most common disorder of the prostate, or the more serious prostate cancer.
Although BPH does not necessarily increase the risk for prostate cancer, both conditions usually coexist. In prostate cases where there are no symptoms, a PSA test is often used to determine BPH or the risk for prostate cancer. Although the standard accepted PSA level is under 4.0 ng/ml, it is ideal to keep it under 1.0 ng/ml.
Studies show that one factor of prostate cancer is higher estrogen and lower testosterone levels which can fuel the overgrowth of prostate tissue. It is therefore important to manage estrogen levels in men.
MYOMIN is an effective natural aromatase reducer that can help reduce estrogen levels in men.
Also, this report on from Johns Hopkins on prostate-related issues:
The Johns Hopkins Prostate Disorders Bulletin
The Johns Hopkins Prostate Disorders Bulletin works with doctors and professors of urology at one of the nation's foremost urological center, we are constantly impressed by the wealth of new therapies, important breakthroughs and newly-discovered preventive measures available to men at high risk for prostate problems, or undergoing treatment for them. Yet for the average medical consumer, the information has simply been inaccessible -- hidden in obscure medical journals or buried in minuscule articles in the back of the daily newspaper. Even many physicians may not have ready access to up-to-the-minute research in this highly specialized field.
As the nation's leading center for prostate care and research, Johns Hopkins' James Buchanan Brady Urological Institute is in a unique position to evaluate and disseminate the very latest information concerning advances in prostate treatment. Now, Dr. Jacek Mostwin is leading a team of world-class prostate specialists as chief medical editor of a remarkable publication created for that precise purpose.
The Johns Hopkins Prostate Disorders Bulletin has one simple mission, one clear focus: to provide those facing prostate health challenges with the kind of authoritative, leading-edge information they need to take charge of their medical care -- intelligently and effectively.
The Johns Hopkins Prostate Disorders Bulletin brings you eye-opening reports about new therapeutic avenues... advance news of clinical trials in which you can participate... detailed answers to subscribers' most pressing questions and concerns... revealing research findings about nutrition, supplementation, lifestyle influences and diagnostic tools... and the latest news from urological and cancer conferences around the world. All with a single relentless focus on prostate issues and the preservation of your health and quality of life, and without mysterious medical jargon -- so you can clearly understand what the advances mean to you.
This can literally be life-changing information -- especially if you fall within the prostate high-risk target zone, which includes men over 40, African-Americans, and any male with a family history of prostate problems. In recent issues,
The Prostate Disorders Bulletin subscribers have learned about:
· Why experts now estimate that up to 90 percent of cancers of the prostate may have a dietary link.
· New evidence that the progression of prostate cancer may actually be slowed by dietary changes. One study published in the Journal of Urology found that tumor cells from men taking flaxseed in combination with a lowfat diet appeared to be growing more slowly and dying more quickly than those of the control group.
· Two types of foods that should be included plentifully in the diet of anyone at risk for prostate problems -- or experiencing them.
· Important prostate issues to consider if you're contemplating testosterone replacement therapy. The good news: most urologists now recommend replacement therapy for men with low testosterone levels -- provided careful follow-up examinations are maintained.
· Must-read comparisons of the robotic-assisted and laparoscopic radical prostatectomy with the traditional radical prostatectomy. You'll get important insights about the relative merits of each approach for curing prostate cancer and maintaining quality of life.
· Why a new use of an oral hormonal medication may represent an important breakthrough in prostate cancer treatment.
· How a team of scientists and physicians is zeroing in on an improved Prostate Specific Antigen (PSA) test -- one which will reduce false positive readings and provide greater accuracy in predicting which men have PSA elevations due to benign prostate enlargement, and which are due to prostate cancer. The Prostate Disorders Bulletin readers will be kept apprised of their success as the data is reported.
· Five questions you should ask your surgeon if you are facing a radical prostatectomy. If he answers negatively to any one of them consider seeking treatment elsewhere. Question #1: does he know and use the nerve-sparing techniques in performing prostate surgery?
· Overactive bladder? You're not alone -- an estimated 17 million Americans, most under the age of 65, are affected by OAB. Your symptoms could be caused by one of the 12 trigger foods we reported on in our latest in-depth report on treating overactive bladder.
· The biggest mistake physicians make in prescribing drugs for prostate enlargement. Important reading for anyone taking Hytrin, Cardura, Flomax or Minipress.
· The pros and cons of medications, minimally-invasive therapies, and surgical alternatives in treating benign prostatic hyperplasia (BPH) -- the most common benign tumor found in men. Dr. Alan W. Partin, M.D., Ph.D, and Distinguished Professor of Urologic Oncology at the Johns Hopkins University School of Medicine reviews treatment options in our in-depth report on BPH.
· Where to find national listings of clinical trials of new therapies for BPH and prostate cancer -- and how you can apply to take part in them.
Source: [
www.johnshopkinshealthalerts.com]
Jackie